Cargando…

Risk factors for treatment interruption and severe adverse effects to benznidazole in adult patients with Chagas disease

BACKGROUND: Etiological treatment of Chagas disease in chronic asymptomatic patients is still in debate and the adverse effects of traditional drugs are one of the main concerns in clinical practice. This study evaluated retrospectively the safety profile of benznidazole (BZN) and identified predict...

Descripción completa

Detalles Bibliográficos
Autores principales: Olivera, Mario J., Cucunubá, Zulma M., Valencia-Hernández, Carlos A., Herazo, Rafael, Agreda-Rudenko, Diana, Flórez, Carolina, Duque, Sofía, Nicholls, Rubén S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5614433/
https://www.ncbi.nlm.nih.gov/pubmed/28949997
http://dx.doi.org/10.1371/journal.pone.0185033
_version_ 1783266404986781696
author Olivera, Mario J.
Cucunubá, Zulma M.
Valencia-Hernández, Carlos A.
Herazo, Rafael
Agreda-Rudenko, Diana
Flórez, Carolina
Duque, Sofía
Nicholls, Rubén S.
author_facet Olivera, Mario J.
Cucunubá, Zulma M.
Valencia-Hernández, Carlos A.
Herazo, Rafael
Agreda-Rudenko, Diana
Flórez, Carolina
Duque, Sofía
Nicholls, Rubén S.
author_sort Olivera, Mario J.
collection PubMed
description BACKGROUND: Etiological treatment of Chagas disease in chronic asymptomatic patients is still in debate and the adverse effects of traditional drugs are one of the main concerns in clinical practice. This study evaluated retrospectively the safety profile of benznidazole (BZN) and identified predictive factors for definite treatment interruption and development of severe reactions in adult patients treated with BZN in Colombia. METHODS: Retrospective follow-up study conducted by review of medical records of adults with chronic Chagas disease treated with BZN in Colombia. A parametric survival analysis based on a generalized gamma distribution was used for assessing risk factors for treatment interruption. A multinomial logistic regression model was used to estimate the probability of severe adverse drug reactions (ADRs). Statistical associations were expressed as time ratios (TR) and adjusted odds ratios (aOR) respectively. RESULTS: In total 224 adults patients treated with BZN were included; 172 (76.8%) completed the standard therapy (60 days of treatment), 205 (91.5%) presented ADRs and 52 cases (23.2%) required treatment interruption. The predominant symptoms were: rash (37.9%), itching (33.7%), epigastric pain (26.4%), abdominal bloating (24.2%) and nausea (22.1%). ADRs were mild (57.4%), moderate (35.5%) and severe (7.3%). Time to treatment interruption was significantly shorter when using doses of BZN ≥ 6 mg/kg/day (TR 0.55; 95% CI 0.39–0.76), presenting severe ADRs (TR 0.12; 95% CI: 0.07–0.19) and eosinophilia (TR 0.68; 95% CI: 0.49–0.94). Female sex (aOR 3.98; 95% CI 1.56–10.16), dose of BZN ≥ 6 mg/kg/day (aOR 1.41; 95% CI 1.17–1.70) and presence of > 3 ADRs (aOR 6.47; 95% CI 1.24–34.34) were considered as risk factors for developing severe ADRs. CONCLUSIONS: Dose, severity of ADRs, eosinophilia and female sex were the main predictors for treatment interruption or severe ADRs. The potential implications of these findings are discussed.
format Online
Article
Text
id pubmed-5614433
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-56144332017-10-09 Risk factors for treatment interruption and severe adverse effects to benznidazole in adult patients with Chagas disease Olivera, Mario J. Cucunubá, Zulma M. Valencia-Hernández, Carlos A. Herazo, Rafael Agreda-Rudenko, Diana Flórez, Carolina Duque, Sofía Nicholls, Rubén S. PLoS One Research Article BACKGROUND: Etiological treatment of Chagas disease in chronic asymptomatic patients is still in debate and the adverse effects of traditional drugs are one of the main concerns in clinical practice. This study evaluated retrospectively the safety profile of benznidazole (BZN) and identified predictive factors for definite treatment interruption and development of severe reactions in adult patients treated with BZN in Colombia. METHODS: Retrospective follow-up study conducted by review of medical records of adults with chronic Chagas disease treated with BZN in Colombia. A parametric survival analysis based on a generalized gamma distribution was used for assessing risk factors for treatment interruption. A multinomial logistic regression model was used to estimate the probability of severe adverse drug reactions (ADRs). Statistical associations were expressed as time ratios (TR) and adjusted odds ratios (aOR) respectively. RESULTS: In total 224 adults patients treated with BZN were included; 172 (76.8%) completed the standard therapy (60 days of treatment), 205 (91.5%) presented ADRs and 52 cases (23.2%) required treatment interruption. The predominant symptoms were: rash (37.9%), itching (33.7%), epigastric pain (26.4%), abdominal bloating (24.2%) and nausea (22.1%). ADRs were mild (57.4%), moderate (35.5%) and severe (7.3%). Time to treatment interruption was significantly shorter when using doses of BZN ≥ 6 mg/kg/day (TR 0.55; 95% CI 0.39–0.76), presenting severe ADRs (TR 0.12; 95% CI: 0.07–0.19) and eosinophilia (TR 0.68; 95% CI: 0.49–0.94). Female sex (aOR 3.98; 95% CI 1.56–10.16), dose of BZN ≥ 6 mg/kg/day (aOR 1.41; 95% CI 1.17–1.70) and presence of > 3 ADRs (aOR 6.47; 95% CI 1.24–34.34) were considered as risk factors for developing severe ADRs. CONCLUSIONS: Dose, severity of ADRs, eosinophilia and female sex were the main predictors for treatment interruption or severe ADRs. The potential implications of these findings are discussed. Public Library of Science 2017-09-26 /pmc/articles/PMC5614433/ /pubmed/28949997 http://dx.doi.org/10.1371/journal.pone.0185033 Text en © 2017 Olivera et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Olivera, Mario J.
Cucunubá, Zulma M.
Valencia-Hernández, Carlos A.
Herazo, Rafael
Agreda-Rudenko, Diana
Flórez, Carolina
Duque, Sofía
Nicholls, Rubén S.
Risk factors for treatment interruption and severe adverse effects to benznidazole in adult patients with Chagas disease
title Risk factors for treatment interruption and severe adverse effects to benznidazole in adult patients with Chagas disease
title_full Risk factors for treatment interruption and severe adverse effects to benznidazole in adult patients with Chagas disease
title_fullStr Risk factors for treatment interruption and severe adverse effects to benznidazole in adult patients with Chagas disease
title_full_unstemmed Risk factors for treatment interruption and severe adverse effects to benznidazole in adult patients with Chagas disease
title_short Risk factors for treatment interruption and severe adverse effects to benznidazole in adult patients with Chagas disease
title_sort risk factors for treatment interruption and severe adverse effects to benznidazole in adult patients with chagas disease
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5614433/
https://www.ncbi.nlm.nih.gov/pubmed/28949997
http://dx.doi.org/10.1371/journal.pone.0185033
work_keys_str_mv AT oliveramarioj riskfactorsfortreatmentinterruptionandsevereadverseeffectstobenznidazoleinadultpatientswithchagasdisease
AT cucunubazulmam riskfactorsfortreatmentinterruptionandsevereadverseeffectstobenznidazoleinadultpatientswithchagasdisease
AT valenciahernandezcarlosa riskfactorsfortreatmentinterruptionandsevereadverseeffectstobenznidazoleinadultpatientswithchagasdisease
AT herazorafael riskfactorsfortreatmentinterruptionandsevereadverseeffectstobenznidazoleinadultpatientswithchagasdisease
AT agredarudenkodiana riskfactorsfortreatmentinterruptionandsevereadverseeffectstobenznidazoleinadultpatientswithchagasdisease
AT florezcarolina riskfactorsfortreatmentinterruptionandsevereadverseeffectstobenznidazoleinadultpatientswithchagasdisease
AT duquesofia riskfactorsfortreatmentinterruptionandsevereadverseeffectstobenznidazoleinadultpatientswithchagasdisease
AT nichollsrubens riskfactorsfortreatmentinterruptionandsevereadverseeffectstobenznidazoleinadultpatientswithchagasdisease